Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. During the day the stock fluctuated 7.29% from a day low at $3.29 to a day high of $3.53. Use POWR Ratings for clearer insight into price direction. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Want to see which stocks are moving? Previously, the target price had yet another drop … 8 Wall Street analysts have issued ratings and price targets for Akebia Therapeutics in the last 12 months. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Find real-time AKBA - Akebia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Learn more. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Analysts on Wall Street suggest a consensus price target of $6.71, implying an increase of 81.35% to the stock’s recent value. Considering analysts have assigned the stock a price target range of $3-$10 as the low and high respectively, we find the trailing 12-month average consensus price target … Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. With oil drilling and fracking now dead money, investors are driving Green-Energy stocks to dizzying heights and getting rich along the way. Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Bitcoin broke through $40,000…. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Fundamental company data provided by Zacks Investment Research. Akebia Therapeutics stock price target cut to $6 from $17 at Mizuho Sep. 4, 2020 at 6:22 a.m. Receive a free world-class investing education from MarketBeat. Enjoy free access to the POWR Ratings for all stocks and ETFs on the quote pages. It is also 69.3% off the consensus price target high of $10.00 offered by 7 analysts, but current levels are -2.33% lower than the price target … The … The extremes give us $3 and $10 for target low and target high price respectively. AKBA has a higher number of analysts covering the stock than 77.9% of stocks in the small market cap category. 4 Wall Street analysts that have issued a 1 year AKBA price target, the average AKBA price target is $10.25, with the highest AKBA stock price forecast at $18.00 and the lowest AKBA stock … AKBA - Akebia Therapeutics Inc Stock quote - CNNMoney.com Markets View which stocks are hot on social media with MarketBeat's trending stocks report. Entry level $4.41 = target price $5.14 Average analysts price target $14.86 | Buy Company profile Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and … ET by Tomi Kilgore Akebia's shares jump on late-stage clinical trial results for kidney disease drug Their average twelve-month price target is $9.63, predicting that the stock has a possible upside of 166.62%. The 12-month stock price forecast is 6.71, which is an increase of 80.38% from the latest price. above. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Looking for new stock ideas? Akebia Therapeutics Inc's variance in analysts' estimates is less than 5.63% of all US stocks. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Our price target ("PT") is $5.17, offering 99% upside. document.write('
'); With oil fracking now dead money under Biden, the Smart Money is flowing into Green-Energy stocks with everyday investors making $millions. The chart below shows how a company's share price and consensus price target have changed over time. Dow Jones, a News Corp company About WSJ. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). You can opt out at any time. According to analyst projections, AKBA’s forecast low is $3 with $10 as the target … All rights reserved. Here’s a brand new clean energy innovator, currently undiscovered at $2 per share, that’s deploying a world’s-first business model with 10X to 20X upside. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. See what's happening in the market right now with MarketBeat's real-time news feed. As such, AKBA has been trading 170.27% off suggested target … Akebia Therapeutics Inc's average analyst price target is greater than 13.77% of all US stocks. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! According to . Get daily stock ideas top-performing Wall Street analysts. Akebia Therapeutics (NASDAQ:AKBA) last issued its earnings results on Wednesday, … Just enter your email address below. This price target is based on 7 analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. If you’re ready to start capitalizing on this massive boom, legendary crypto investor Matt McCall just released a new free report, “3 Cryptos to Beat Bitcoin.”, Start Your Risk-Free Trial Subscription Here, Editor of top German newspaper suspended in compliance probe, Timing key in consulting deal between FirstEnergy, regulator, You Must Recognize Your Own Achievements First Before Expecting Others To, The Latest: Paris may face new lockdown as ICUs fill up, 'Big burden' for schools trying to give kids internet access, The Latest: Pakistan imposes partial lockdown in some areas, Three Mall Retailers For Your Reopening Watchlist, 3 Growth Stocks with Above Market Dividend Yields, 3 Best Stocks to Buy That You’ve Probably Never Heard Of, Ferroglobe Will Get a Big Lift From Demand For Silcon Wafers, Blue Bird Stock is a Dual Tailwinds EV and Re-Opening Play, Nautilus Stock is a Pullback Buying Opportunity Here, The Launch of Truforma Should Send Zomedica to An All-Time High, Defi Markets Pause But New Highs Are In Sight, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, Oil is Dead Money: Green-Energy Stocks Are Booming, Receive Analysts' Upgrades and Downgrades Daily. appreciate its future potential. Price Target According to 8 analysts, the average rating for AKBA stock is "Buy." To see all exchange delays and terms of use please see disclaimer. The company has a consensus rating of “Hold” and an average price target of $9.22. The stock has a fifty day moving average price of $3.88 and a 200-day moving average price of $3.49. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Join. Last 30 Days. AKBA has a higher upside potential (average analyst target price relative to current price) than 88.09% of all US stocks. Price *Price Target Lowest: 3.00 Median: 11.64 Highest: 18.00 *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. AKBA updated stock price target summary. What is the outlook for AKBA? Learn more. The dark blue line represents the company's actual price. … Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Login The median AKBA price target (a different metric than the average or mean) was $8.5 as of 2021-03-07, the highest AKBA price target in the range was $18.0 while the lowest AKBA price target in the range was $3.0, with a standard deviation of $6.047. The price target was set to $10.00 → $9.00. The high price target for AKBA is $18.00 and the low price target for AKBA is $3.00. Man Gets Into a Tesla… What Happens Next Will Shock Everyone (Video), "Hi, I'm Jeff Brown… I'm about to get in this Tesla and drive up to a location just a few miles from here to show you Elon Musk's next big project… AKBA has a higher number of analysts covering the stock than 77.9% of stocks in the small market cap category. The cryptocurrency market is exploding in value right now… Ratings...FREE! MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. They currently have a buy rating on the biopharmaceutical company’s stock. Just click the link
Their average twelve-month price target is $9.63, predicting that the stock has a … Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. All 'A' Rated Buy Stocks. The consensus price target for the stock as assigned by Wall Street analysts is $6.5, meaning bulls need an upside of 91.74% from its recent market value. Identify stocks that meet your criteria using seven unique stock screeners. Shares of Akebia Therapeutics stock … Akebia Therapeutics, Inc. (NASDAQ:AKBA)’s beta value is holding at 1.83, while the average true range (ATR) indicator is currently reading 0.37. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. On average, they expect Akebia Therapeutics' share price to … Share your opinion and gain insight from other stock traders and investors. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. The analyst firm set a price target for 0.00 expecting AKBA to fall to within 12 … Sign Up to See
© American Consumer News, LLC dba MarketBeat® 2010-2021. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Akebia Therapeutics (NASDAQ:AKBA) had its price target cut by HC Wainwright from $9.00 to $6.00 in a research report sent to investors on Monday morning, The Fly reports. Use POWR Ratings for clearer insight into price direction. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Akebia Therapeutics (NASDAQ: AKBA) was reported by JP Morgan on 2021-01-29. View Price Target for AKBA Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. The AKBA stock was last observed hovering at around $2.99 in the last trading session, with the day’s gains setting it 0.08% off its average median price target of $7.00 for the next 12 months. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. We have 9 different ratings for every stock to help you
There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy.". Learn about financial terms, types of investments, trading strategies and more. Akebia Therapeutics Inc's average analyst price target is greater than 13.77% of all US stocks. Export data to Excel for your own analysis. Get short term trading ideas from the MarketBeat Idea Engine. Based on analysts offering 12 month price targets for AKBA in the last 3 months.
Memento Database Inventory,
Jobs In Arab, Al,
Buffaloed Movie Australia,
City Of North Port Building Permit Search,
Best Radio Stations In Alabama,
Bring Back Eqoa,
Found Cats Langford Bc,
Dove dormire
